Mr. James Howard-Tripp reports
THE PROSTATE HEALTH INDEX, A BLOOD TEST FOR PROSTATE CANCER DETECTION, IS NOW AVAILABLE TO CONSUMERS NATIONWIDE THROUGH GENENEWS' NATIONAL TELEHEALTH PROGRAM
GeneNews Ltd. has launched its first telehealth program for marketing the Prostate Health Index (PHI) directly to patients nationwide. The Prostate Health Index is a Food and Drug Administration-approved blood test that can help differentiate prostate cancer from benign prostate conditions in men with elevated prostate-specific antigen.
The Prostate Health Index is quickly becoming the "second opinion" for men with elevated PSA who want more information before deciding to move forward with a prostate biopsy. While prostate-specific antigen is currently the most used screening test for prostate cancer, it is widely recognized that PSA results can indicate the possibility of prostate cancer when none is present. The Prostate Health Index utilizes three different PSA markers (PSA, freePSA and p2PSA) as part of a sophisticated algorithm to more reliably determine the probability of cancer in patients with elevated PSA levels, and can help men and their physicians decide if a prostate biopsy is indicated.
Addressing an unmet need
"We launched this program to address the hundreds of patient inquiries we get for the Prostate Health Index," commented James Howard-Tripp, chairman and chief executive officer. "Men want a greater say in their treatment and want these tests done at their request, timelines and convenience. When you are at risk for having prostate cancer, you want to know what your next step should be. Now, through a telehealth physician network that is familiar with the clinical utility of the test, we have a solution that can address a patient's immediate need to get tested and to help guide their management."
Studies have shown that approximately 70 per cent of men with an elevated PSA who have a biopsy do not have cancer. The Prostate Health Index is included in the National Comprehensive Cancer Network (NCCN) guideline for prostate cancer early detection as a blood test to improve specificity for prostate cancer detection.
How it works
The Prostate Health Index is indicated for men aged 50 and older with an elevated PSA between four nanograms per millilitre and 10 nanograms per millilitre. Once an order is submitted, GeneNews will connect the patient with a physician in its U.S.-based telehealth partner network who can prescribe the test after confirming the patient is eligible. GeneNews will then connect the patient with a convenient blood draw location or mobile phlebotomist.
The test is processed at the company's CLIA- and CAP-accredited reference laboratory located in Richmond, Va. Results are reported back to the ordering telehealth physician, who will review the results with the patient. Patients are advised to share their test report with their regular health care professionals so that results can be integrated into their treatment plans.
Patients pay a flat fee of $299, which covers the physician order, blood draw charges, the test and physician consult, as required.
About GeneNews Ltd.
GeneNews is dedicated to developing and commercializing innovative solutions for early cancer detection. The company's mission is to provide advanced diagnostics that can help physicians identify cancer in their patients at the earliest-possible stage, when it is the most curable.
© 2019 Canjex Publishing Ltd. All rights reserved.